{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:08:56Z","timestamp":1792512536864,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The use of immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is gaining momentum. However, evidence regarding the feasibility and safety of pre-LT ICI therapy remains limited and controversial. This study presents our experience with patients with intermediate-advanced HCC who were downstaged using regimens incorporating ICIs and subsequently underwent living donor LT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We retrospectively reviewed the medical records of 10 patients with Barcelona Clinic Liver Cancer stage B or C HCC treated with locoregional therapies (LRTs), ICIs, and living donor LT at Chang Gung Memorial Hospital at Linkou between 2021 and 2024.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In total, 10 recipients received pre-LT ICI-based downstaging therapy, with 8 also undergoing concomitant LRTs. Two patients experienced grade III immune-related hepatitis. The median ICI washout period before LT was 149 d. Posttransplantation, 5 patients developed allograft rejection, which was managed effectively with routine steroid therapy. Notably, 4 patients demonstrated a complete pathological response. After a median post-LT follow-up of 15.5 mo (interquartile range, 8\u201325 mo), 2 patients experienced tumor recurrence. The 12- and 24-mo overall survival rates post-LT were 75%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Selected patients with advanced, initially untransplantable HCC can benefit from a multimodal approach involving LRTs combined with ICIs, enabling successful LT. These findings suggest a potential paradigm shift in the treatment of intermediate-advanced HCC, warranting further investigation in larger cohorts and longer-term studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001852","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:03:30Z","timestamp":1758225810000},"page":"e1852","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pretransplant Immune Checkpoint Inhibitor Treatment for Intermediate-advanced Hepatocellular Carcinoma in Living Donor Liver Transplantation"],"prefix":"10.1097","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-0631","authenticated-orcid":false,"given":"Chih-Hsien","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wen","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chien","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chiao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Fang","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jung","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Shiue","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Liver and Transplantation Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.","volume":"79","author":"Norman","year":"2023","journal-title":"J Hepatol"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/TP.0000000000003196","article-title":"Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.","volume":"104","author":"Berenguer","year":"2020","journal-title":"Transplantation"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial.","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"R7-20250918","first-page":"1","article-title":"Number of tumors stratifies the therapeutic response to atezolizumab plus bevacizumab therapy in Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: a multicenter analysis.","author":"Suzuki","year":"2020","journal-title":"Oncology (Huntingt)"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"e430028","DOI":"10.1200\/EDBK_430028","article-title":"Updates on systemic therapy for hepatocellular carcinoma.","volume":"44","author":"Ntellas","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R9-20250918","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3390\/cancers16051043","article-title":"Impact of pre-liver transplant treatments on the imaging accuracy of HCC staging and their influence on outcomes.","volume":"16","author":"Franchi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study.","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis.","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transplant"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MOT.0000000000001133","article-title":"Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy.","volume":"29","author":"Tabrizian","year":"2024","journal-title":"Curr Opin Organ Transplant"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.3390\/cancers15184574","article-title":"Immunotherapy and liver transplantation: a narrative review of basic and clinical data.","volume":"15","author":"Wassmer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/ajt.14549","article-title":"Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.","volume":"18","author":"Mehta","year":"2018","journal-title":"Am J Transplant"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"39881","DOI":"10.1038\/srep39881","article-title":"Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation.","volume":"7","author":"Grat","year":"2017","journal-title":"Sci Rep"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.3390\/cancers13174403","article-title":"Risk score model for microvascular invasion in hepatocellular carcinoma: the role of tumor burden and alpha-fetoprotein.","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.21037\/jgo-22-922","article-title":"Immune checkpoint inhibitors in liver transplant: a case series.","volume":"14","author":"Rudolph","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:03:33Z","timestamp":1758225813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001852","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}